Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

@article{EtienneGrimaldi2010MethylenetetrahydrofolateR,
  title={Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.},
  author={Marie-Christine Etienne-Grimaldi and G{\'e}rard Milano and Fr{\'e}d{\'e}rique Maindrault-Goebel and Benoist Chibaudel and J. L. Formento and Mireille Francoual and G{\'e}rard Lledo and Thierry Andr{\'e} and May Mabro and Laurent Mineur and Michel Flesch and Elisabeth Carola and Aimery de Gramont},
  journal={British journal of clinical pharmacology},
  year={2010},
  volume={69 1},
  pages={58-66}
}
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Numerous clinical studies, including a few prospective ones, have reported conflicting results on the impact of gene polymorphisms related to fluorouracil (FU) and oxaliplatin pharmacodynamics. WHAT THIS STUDY ADDS * This prospective study is the first to report that clinical response to FOLFOX is significantly related to methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms (677C-->T and 1298A-->C), with a response rate of 37, 53, 63 and 80… CONTINUE READING